Subject
Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of advanced renal cell carcinoma (kidney cancer). It is an oral VEGF receptor tyrosine kinase inhibitor. The most common side effects include fatigue (tiredness), hypertension (high blood pressure), diarrhea, decreased appetite, nausea, dysphonia (voice changes), hypothyroidism, cough, and stomatitis. Tivozanib was approved for medical use in the European Union in August 2017, and in the United States in March 2021. Source: Wikipedia (en)
Works about tivozanib
There is nothing here
Subject - wd:Q7810457